Dr Reddys Laboratories Ltd 6-K, filed May 21, 2020
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on May 21, 2020.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May, 2020
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
| Exhibit Number |
Description of Exhibits | |
| 99.1 | Intimation | |
| 99.2 | Board meeting outcome |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
| Date: May 20, 2020 | By: | /s/ Sandeep Poddar | |
| Name: | Sandeep Poddar | ||
| Title: | Company Secretary | ||
Exhibit 99.1
 |
Dr. Reddy's Laboratories Ltd. |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 |
| Tel | :+91 40 4900 2900 | |
| Fax | :+91 40 4900 2999 | |
| :mail@drreddys.com | ||
| www.drreddys.com | ||
May 20, 2020
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 /22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EO |
Dear Sirs,
Sub: Intimation
Further to our intimation dated February 28, 2020 with regard to the audit of our Formulations Manufacturing Plant – 3 at Bachupally, Hyderabad, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit.
This is for your information.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
Exhibit 99.2
 |
Dr. Reddy's Laboratories Ltd. |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN : L85195TG1984PLC004507 |
| Tel | :+91 40 4900 2900 | |
| Fax | :+91 40 4900 2999 | |
| :mail@drreddys.com | ||
| www.drreddys.com | ||
May 20, 2020
The Secretary I Executive Director
BSE Limited
National Stock Exchange of India Ltd.
Dear Sir/Madam,
Sub: Board meeting outcome.
This is to inform you that based on the recommendation of Nomination, Governance and Compensation Committee, the Board of Directors of the Company, at its meeting held on 20 May, 2020 has re-appointed Mr. G V Prasad (DIN: 00057433) as Whole-time Director designated as Co-Chairman and Managing Director of the Company for a further period of 5 years i.e. from January 30, 2021 to January 29, 2026, subject to approval of shareholders of the Company at the ensuing Annual General Meeting.
This is for your information and records.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)